California, USA-based Rakuten Medical and India’s Karkinos Healthcare Private Limited have announced a strategic collaboration to expand the reach of novel cancer care to India.
This includes a minority stake acquisition in Karkinos by Rakuten Medical, whose investment marks Karkinos’ first international investor.
Rakuten Medical is focused on developing and commercializing innovative cancer treatments for multiple indications based on its Illuminox platform. Karkinos is a healthcare technology platform focused on delivering quality healthcare by providing access to, and availability of, cancer detection, diagnosis and treatment options. This strategic collaboration will enable continued innovation in cancer care with the goal of transforming cancer care in India and abroad.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze